An update from Sandoz Group Ltd ( (CH:SDZ) ) is now available.
Sandoz has entered a global collaboration agreement with Shanghai Henlius Biotech to commercialize a biosimilar of the oncology therapy ipilimumab, targeting net reference medicine sales of USD 2.5 billion. This agreement, which includes a milestone-based consideration of up to USD 301 million, grants Sandoz exclusive commercial rights in major markets like the US and Europe. The collaboration aims to address unmet medical needs and expand patient access to cancer treatments, reinforcing Sandoz’s commitment to sustainable healthcare solutions.
More about Sandoz Group Ltd
Sandoz is a global leader in generic and biosimilar medicines, headquartered in Basel, Switzerland. The company has a rich history of pioneering medical breakthroughs, including the world’s first biosimilar in 2006. Sandoz employs over 20,000 people of 100 nationalities and offers a portfolio of approximately 1,300 products, addressing a wide range of diseases and generating significant global healthcare savings.
YTD Price Performance: 8.66%
Average Trading Volume: 3,798
Technical Sentiment Signal: Strong Sell
Current Market Cap: $19.28B
Find detailed analytics on SDZ stock on TipRanks’ Stock Analysis page.